PT3818086T - Tratamento e prevenção de cancro usando moléculas de ligação ao antigénio her3 - Google Patents
Tratamento e prevenção de cancro usando moléculas de ligação ao antigénio her3Info
- Publication number
- PT3818086T PT3818086T PT207805722T PT20780572T PT3818086T PT 3818086 T PT3818086 T PT 3818086T PT 207805722 T PT207805722 T PT 207805722T PT 20780572 T PT20780572 T PT 20780572T PT 3818086 T PT3818086 T PT 3818086T
- Authority
- PT
- Portugal
- Prior art keywords
- cancer
- prevention
- treatment
- binding molecules
- her3 antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1913079.8A GB201913079D0 (en) | 2019-09-11 | 2019-09-11 | Treatment and prevention of cancer using her3 antigen-binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3818086T true PT3818086T (pt) | 2021-10-26 |
Family
ID=68241208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT207805722T PT3818086T (pt) | 2019-09-11 | 2020-09-10 | Tratamento e prevenção de cancro usando moléculas de ligação ao antigénio her3 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11208498B2 (https=) |
| EP (2) | EP3818086B1 (https=) |
| JP (2) | JP7708741B2 (https=) |
| KR (1) | KR20220086554A (https=) |
| CN (2) | CN116059347A (https=) |
| AU (1) | AU2020347473A1 (https=) |
| BR (1) | BR112022004474A8 (https=) |
| CA (1) | CA3149853A1 (https=) |
| DK (1) | DK3818086T3 (https=) |
| ES (1) | ES2896921T3 (https=) |
| GB (1) | GB201913079D0 (https=) |
| MX (1) | MX2022002977A (https=) |
| PL (1) | PL3818086T3 (https=) |
| PT (1) | PT3818086T (https=) |
| TW (1) | TWI883044B (https=) |
| WO (1) | WO2021048274A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3433273T (pt) | 2016-03-25 | 2022-02-21 | Biomunex Pharmaceuticals | Moléculas de ligação a cd38 e pd-l1 |
| SG11201809316XA (en) * | 2016-04-28 | 2018-11-29 | Biomunex Pharmaceuticals | Bispecific antibodies targeting egfr and her2 |
| KR20240125061A (ko) | 2017-03-27 | 2024-08-19 | 바이오뮤넥스 파마슈티컬스 | 안정적인 다중특이적 항체 |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| CN114790462B (zh) * | 2021-01-25 | 2023-10-31 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 靶向bcma的嵌合抗原受体及其应用 |
| CN112961865B (zh) * | 2021-02-22 | 2023-06-02 | 广西大学 | 一种利用基因编辑鸡生物反应器表达的重组曲妥珠单抗及应用 |
| EP4304636A1 (en) * | 2021-03-11 | 2024-01-17 | Elevation Oncology, Inc. | Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions |
| TW202313987A (zh) * | 2021-06-03 | 2023-04-01 | 荷蘭商美勒斯公司 | 用於測定nrg1融合多核苷酸的液態檢體測定法 |
| JP2024523001A (ja) * | 2021-06-03 | 2024-06-25 | メルス ナムローゼ フェンノートシャップ | 新たなｎｒｇ１融合体、融合接合部及びそれらを検出するための方法 |
| GB202108449D0 (en) | 2021-06-14 | 2021-07-28 | Hummingbird Bioscience Holdings Pte Ltd | Cells expressing her3 antigen-binding molecules |
| US20250136712A1 (en) | 2021-08-13 | 2025-05-01 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using her3 antigen-binding molecules |
| JP2024536719A (ja) * | 2021-09-03 | 2024-10-08 | キャンサー・リサーチ・テクノロジー・リミテッド | Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防 |
| CN116333118B (zh) * | 2021-12-16 | 2024-04-19 | 徕特康(苏州)生物制药有限公司 | 抗表皮生长因子受体抗体及其制备方法和用途 |
| US20240117030A1 (en) * | 2022-03-03 | 2024-04-11 | Pfizer Inc. | Multispecific antibodies and uses thereof |
| WO2024121163A1 (en) | 2022-12-06 | 2024-06-13 | Cancer Research Technology Limited | Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers |
| CN120417924A (zh) | 2022-12-07 | 2025-08-01 | 蜂鸟生物科技私人有限公司 | 治疗和预防癌症的组合疗法 |
| WO2024147097A1 (en) | 2023-01-03 | 2024-07-11 | Hummingbird Bioscience Pte. Ltd. | Her3-binding antibody-drug conjugate |
| EP4687972A1 (en) | 2023-04-06 | 2026-02-11 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using her3 antigen-binding molecules |
| KR20260022498A (ko) | 2023-04-14 | 2026-02-19 | 허밍버드 바이오사이언스 피티이. 엘티디. | 암의 치료 및 예방을 위한 조합물 |
| WO2025057173A2 (en) * | 2023-09-14 | 2025-03-20 | B.G. Negev Technologies And Applications Ltd. | Ligand-based chimeric antigen receptors and uses thereof |
| WO2025056781A1 (en) | 2023-09-15 | 2025-03-20 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using her3-binding molecules |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP1283053A1 (en) * | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| MY152068A (en) * | 2009-03-20 | 2014-08-15 | Genentech Inc | Bispecific anti-her antibodies |
| EP2571901B1 (en) * | 2010-05-20 | 2019-01-02 | Ablynx N.V. | Biological materials related to her3 |
| CN104105709A (zh) * | 2011-12-05 | 2014-10-15 | 诺华股份有限公司 | 抗her3的结构域ii的表皮生长因子受体3(her3)抗体 |
| US20130259867A1 (en) * | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
| EP2961773B1 (en) | 2013-02-26 | 2019-03-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| WO2014182970A1 (en) * | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
| EP3085781A1 (en) | 2013-12-19 | 2016-10-26 | National Cancer Center | Novel fusion gene as factor responsible for stomach cancer |
| WO2016059602A2 (en) * | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| JP6180663B2 (ja) * | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| EP3091033A1 (en) * | 2015-05-06 | 2016-11-09 | Gamamabs Pharma | Anti-human-her3 antibodies and uses thereof |
| IL269656B2 (en) | 2017-03-31 | 2024-06-01 | Merus Nv | Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene |
| EP3679063A4 (en) | 2017-09-08 | 2021-06-02 | The Regents of The University of Colorado, A Body Corporate | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OR PREVENTION OF HER-CONTROLLED DRUG-RESISTANT CANCER |
| US20190300610A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
| WO2019185164A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
-
2019
- 2019-09-11 GB GBGB1913079.8A patent/GB201913079D0/en not_active Ceased
-
2020
- 2020-09-10 AU AU2020347473A patent/AU2020347473A1/en active Pending
- 2020-09-10 CN CN202211117480.0A patent/CN116059347A/zh active Pending
- 2020-09-10 PT PT207805722T patent/PT3818086T/pt unknown
- 2020-09-10 EP EP20780572.2A patent/EP3818086B1/en active Active
- 2020-09-10 EP EP21180956.1A patent/EP3943509A1/en active Pending
- 2020-09-10 JP JP2022516173A patent/JP7708741B2/ja active Active
- 2020-09-10 KR KR1020227011181A patent/KR20220086554A/ko active Pending
- 2020-09-10 BR BR112022004474A patent/BR112022004474A8/pt unknown
- 2020-09-10 MX MX2022002977A patent/MX2022002977A/es unknown
- 2020-09-10 CA CA3149853A patent/CA3149853A1/en active Pending
- 2020-09-10 ES ES20780572T patent/ES2896921T3/es active Active
- 2020-09-10 WO PCT/EP2020/075319 patent/WO2021048274A1/en not_active Ceased
- 2020-09-10 DK DK20780572.2T patent/DK3818086T3/da active
- 2020-09-10 PL PL20780572T patent/PL3818086T3/pl unknown
- 2020-09-10 TW TW109131184A patent/TWI883044B/zh active
- 2020-09-10 CN CN202080009114.6A patent/CN113347994B/zh active Active
-
2021
- 2021-01-20 US US17/153,705 patent/US11208498B2/en active Active
- 2021-11-24 US US17/535,313 patent/US20220153870A1/en active Pending
-
2025
- 2025-07-02 JP JP2025112447A patent/JP2025143396A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220086554A (ko) | 2022-06-23 |
| TWI883044B (zh) | 2025-05-11 |
| CN116059347A (zh) | 2023-05-05 |
| JP7708741B2 (ja) | 2025-07-15 |
| PL3818086T3 (pl) | 2022-03-14 |
| US20210155712A1 (en) | 2021-05-27 |
| GB201913079D0 (en) | 2019-10-23 |
| US11208498B2 (en) | 2021-12-28 |
| CN113347994B (zh) | 2022-09-23 |
| BR112022004474A2 (pt) | 2022-06-21 |
| CA3149853A1 (en) | 2021-03-18 |
| DK3818086T3 (da) | 2021-10-04 |
| TW202123926A (zh) | 2021-07-01 |
| EP3943509A1 (en) | 2022-01-26 |
| AU2020347473A1 (en) | 2022-03-31 |
| MX2022002977A (es) | 2022-07-12 |
| BR112022004474A8 (pt) | 2023-01-17 |
| ES2896921T3 (es) | 2022-02-28 |
| JP2025143396A (ja) | 2025-10-01 |
| EP3818086B1 (en) | 2021-08-04 |
| WO2021048274A1 (en) | 2021-03-18 |
| JP2022548057A (ja) | 2022-11-16 |
| EP3818086A1 (en) | 2021-05-12 |
| US20220153870A1 (en) | 2022-05-19 |
| CN113347994A (zh) | 2021-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3818086T (pt) | Tratamento e prevenção de cancro usando moléculas de ligação ao antigénio her3 | |
| IL313807A (en) | Claudin 18 antibodies and methods for cancer treatment | |
| IL273196A (en) | Claudin 6 antibodies and methods of cancer treatment | |
| IL279347A (en) | Gremlin-1 antagonist for cancer prevention and treatment | |
| EP3270966A4 (en) | Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer | |
| IL277981A (en) | Cancer treatment methods | |
| SG11202011117VA (en) | Treatment of cancer | |
| IL272669A (en) | Combination therapy with a combination of anti-CSF1R and anti-PD-1 antibodies for pancreatic cancer | |
| IL286297A (en) | Minimal residual cancer treatment methods | |
| SG11202010793UA (en) | Methods of treating cancer | |
| IL281600B2 (en) | Cancer treatment methods | |
| IL276203A (en) | Compounds and methods for treating cancer | |
| GB201919428D0 (en) | Immunotherapeutic treatment of cancer | |
| SG11202109097UA (en) | Materials and methods for enhanced treatment and prevention of biofilms | |
| IL289811A (en) | A method for treating cancer | |
| IL279591A (en) | Cancer treatment methods using combination therapy | |
| SG11202107017TA (en) | Methods of treating cancer | |
| IL267613A (en) | Pancreatic cancer treatment | |
| IL287538A (en) | Preparations and methods for the treatment of cancer | |
| SI3630112T1 (sl) | Kombinacija regorafeniba in nivolumaba za zdravljenje raka | |
| IL288178A (en) | Combined gmci and ddri treatment for cancer | |
| GB202107994D0 (en) | Treatment of cancer | |
| IL276905A (en) | Treatment and prevention of preeclampsia | |
| GB201918692D0 (en) | Treatment and prognosis of pancreatic cancer | |
| GB201820098D0 (en) | Methods of cancer treatment |